TrialBMC cancer2012

A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.

Anne Katrin Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.